# Protox completes botulinum toxin plant in Hwaseong, South Korea

Protox, a DSK subsidiary, held a completion ceremony for its botulinum toxin bio-production plant in Hwaseong, Gyeonggi Province. The plant cost about KRW 32 billion and has a total floor area of 6,227 m² over four floors with GMP facilities. It can produce 2.7 million vials of botulinum toxin annually.

- Type: New facility
- Announced: 2019-04-26
- Where: Hwaseong, Gyeonggi Province, South Korea
- Value: $27.0M (32.0B KRW)
- Starts operating: 25 Apr 2019
- Status: completed
- Capacity: 2.7 million vials per year
- Products: botulinum toxin
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Protox](https://endata.com/companies/39045.md)
- [DSK](https://endata.com/companies/39046.md) (investor)

## Sources

- [m.dailypharm.com](https://m.dailypharm.com/user/news/75154), 2019-04-26: "프로톡스는 이번 공장 준공을 계기로 연간 270만 바이알 규모의 보툴리눔 톡신 제제를 생산할 수 있으며"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.